Breast cancer subtypes and the risk of local and regional relapse

Journal of Clinical Oncology

Volumn 28, Issue 10, 2010, Pages 1684-1691

  Voduc, K David ^a   Cheang, Maggie C U ^a   Tyldesley, Scott ^a   Gelmon, Karen ^a   Nielsen, Torsten O ^a   Kennecke, Hagen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASTECTOMY; PRIORITY JOURNAL; RISK ASSESSMENT; TISSUE MICROARRAY; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; NEOPLASM; PATHOLOGY; TUMOR RECURRENCE;

ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77950512587     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.9284     Document Type: Article

References (41)

1. Casalini P, Carcangiu ML, Tammi R, et al: Two distinct local relapse subtypes in invasive breast cancer: Effect on their prognostic impact. Clin Cancer Res 14:25-31, 2008 (Pubitemid 351377974)
2. Haffty BG, Hauser A, Choi DH, et al: Molecular markers for prognosis after isolated postmastectomy chest wall recurrence. Cancer 100:252-263, 2004 (Pubitemid 38063632)
3. Punglia RS, Morrow M, Winer EP, et al: Local therapy and survival in breast cancer. N Engl J Med 356:2399-2405, 2007
4. Clarke M, Collins R, Darby S, et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 366:2087-2106, 2005 (Pubitemid 41797643)
5. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
6. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001 (Pubitemid 32878711)
7. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
8. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003 (Pubitemid 36842560)
9. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004 (Pubitemid 40051905)
10. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
11. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374, 2004 (Pubitemid 39100473)
12. Cheang MC, Voduc D, Bajdik C, et al: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368-1376, 2008 (Pubitemid 351413917)
13. Cheang MC, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736-750, 2009
14. Olivotto A, Coldman AJ, Hislop TG, et al: Compliance with practice guidelines for node-negative breast cancer. J Clin Oncol 15:216-222, 1997 (Pubitemid 27020576)
15. Cheang MC, Treaba DO, Speers CH, et al: Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24:5637-5644, 2006 (Pubitemid 46631303)
16. Sanghani M, Balk E, Cady B, et al: Predicting the risk of local recurrence in patients with breast cancer: An approach to a new computer-based predictive tool. Am J Clin Oncol 30:473-480, 2007 (Pubitemid 47537946)
17. Nottage MK, Kopciuk KA, Tzontcheva A, et al: Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: A prospective cohort study. Breast Cancer Res 8:R44, 2006
18. Grambsch P, Louis TA, Bostick RM, et al: Statistical analysis of proliferative index data in clinical trials. Stat Med 13:1619-1634, 1994 (Pubitemid 24275841)
19. Millar EK, Graham PH, O'Toole SA, et al: Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27:4701-4708, 2009
20. Nguyen PL, Taghian AG, Katz MS, et al: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373-2378, 2008
21. Haffty BG, Yang Q, Reiss M, et al: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652-5657, 2006 (Pubitemid 46631305)
22. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434, 2007 (Pubitemid 47219710)
23. Kyndi M, Sorensen FB, Knudsen H, et al: Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol 26:1419-1426, 2008
24. Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b trial. N Engl J Med 337:949-955, 1997 (Pubitemid 27425950)
25. Overgaard M, Jensen MB, Overgaard J, et al: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353:1641-1648, 1999 (Pubitemid 29224519)
26. Ragaz J, Jackson SM, Le N, et al: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956-962, 1997 (Pubitemid 27425951)
27. Truong PT, Lesperance M, Culhaci A, et al: Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy. Int J Radiat Oncol Biol Phys 62:175-182, 2005 (Pubitemid 40591940)
28. Truong PT, Bernstein V, Wai E, et al: Age-related variations in the use of axillary dissection: A survival analysis of 8038 women with T1-ST2 breast cancer. Int J Radiat Oncol Biol Phys 54:794-803, 2002
29. Martelli G, Miceli R, Costa A, et al: Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: Fifteen-year results of a prospective study. Cancer 112:481-488, 2008 (Pubitemid 351186188)
30. Crabb SJ, Cheang MC, Leung S, et al: Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer 8:249-256, 2008 (Pubitemid 351962146)
31. Fulford LG, Reis-Filho JS, Ryder K, et al: Basal-like grade III invasive ductal carcinoma of the breast: Patterns of metastasis and long-term survival. Breast Cancer Res 9:R4, 2007
32. Colleoni M, Rotmensz N, Peruzzotti G, et al: Minimal and small size invasive breast cancer with no axillary lymph node involvement: The need for tailored adjuvant therapies. Ann Oncol 15:1633-1639, 2004 (Pubitemid 39562603)
33. Mamounas E, Tang G, Bryant J: Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2005 (abstr 29)
34. de Roos MA, de Bock GH, de Vries J, et al: P53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. J Surg Res 140:109-114, 2007 (Pubitemid 46669545)
35. Koukourakis MI, Giatromanolaki A, Galazios G, et al: Molecular analysis of local relapse in high-risk breast cancer patients: Can radiotherapy fractionation and time factors make a difference? Br J Cancer 88:711-717, 2003
36. Zellars RC, Hilsenbeck SG, Clark GM, et al: Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol 18:1906-1913, 2000
37. Hieken TJ, Farolan M, D'Alessandro S, et al: Predicting the biologic behavior of ductal carcinoma in situ: An analysis of molecular markers. Surgery 130:593-600, 2001
38. Ringberg A, Anagnostaki L, Anderson H, et al: Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 37:1514-1522, 2001 (Pubitemid 32744682)
39. Elkhuizen PH, Voogd AC, van den Broek LC, et al: Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: A case-control study of histological factors and alterations in oncogene expression. Int J Radiat Oncol Biol Phys 45:73-83, 1999 (Pubitemid 29380077)
40. Jager JJ, Jansen RL, Arends JW, et al: Anti-apoptotic phenotype is associated with decreased locoregional recurrence rate in breast cancer. Anticancer Res 20:1269-1275, 2000 (Pubitemid 30240712)
41. Nuyten DS, Kreike B, Hart AA, et al: Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8:R62, 2006